Recombinant Human Neuroligin 2/NLGN2 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Neuroligin 2/NLGN2 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Neuroligin 2/NLGN2 is immobilized at 1.5 μg/mL, Recombinant Human Neurexin 1 beta /NXRN1b Fc Chimera (Catalog # 5268-NX) binds with an apparent K_d <10 nM.
• Source: Mouse myeloma cell line, NS0-derived human Neuroligin 2/NLGN2 protein
  Gln15-Ser660, with a C-terminal 6-His tag
• Accession #: EAW90197
• N-terminal Sequence: No results obtained: Gln15 predicted
• Protein/Peptide Type: Recombinant Proteins
• Gene: NLGN2
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 72 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 85-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Neuroligin 2/NLGN2 Protein, CF

• EC 3.1.1
• EC 3.1.1.1
• KIAA1366neuroligin-2
• Neuroligin 2
• NLGN2

Background

Neuroligin 2 (NLGN2) is one of several type I transmembrane Neuroligins that are expressed on neuronal postsynaptic densities. Neuroligins play an important role in synaptic development and function (1). Mature human Neuroligin 2 is a 105 kDa protein that consists of a 663 amino acid (aa) extracellular domain (ECD) with a catalytically inactive cholinesterase-like domain, a 21 aa transmembrane segment, and a 137 aa cytoplasmic tail (2, 3). Within the ECD, human Neuroligin 2 shares 98% aa sequence identity with mouse and rat Neuroligin 2. Alternate splicing generates an isoform with a 17 aa insertion at splice site A within the ECD (2). This recombinant protein does not contain the splice site A insert (-SS A). Neuroligin 2 is expressed on neurons in the brain and also on pancreatic beta  cells where it facilitates insulin secretion (2, 4, 5). The -SS A isoform is uniformly expressed among inhibitory and excitatory synapses, while the +SS A isoform is enriched at inhibitory GABAergic synapses (4, 6, 7). Neuroligin 2 clusters at postsynaptic densities in association with other postsynaptic proteins including S-SCAM, PSD-95, gephyrin, and Neuroligin 3 (4, 8-10). Synaptic maturation is promoted by the binding of Neuroligin 2 with presynaptic Neurexins, and these interactions are restricted to particular combinations of isoforms of the binding partners (11-15). Neuroligin 2 interacts with the alpha and beta forms of Neurexin 1, 2, and 3 (14). Its -SS A and +SS A isoforms are bound equally well by Neurexin 1 beta isoforms (-SS4 or +SS4), although only the Neurexin 1 beta +SS4 isoform can induce development of Neuroligin 2-dependent GABAergic contacts (7, 15).

1. Sudhof, T.C. (2008) Nature 455:903.
2. Ichtchenko, K. et al. (1996) J. Biol. Chem. 271:2676.
3. Koehnke, J. et al. (2008) Proc. Natl. Acad. Sci. 105:1873.
4. Varoqueaux, F. et al. (2004) Eur. J. Cell Biol. 83:449.
5. Suckow, A.T. et al. (2008) Endocrinology 149:6006.
6. Graf, E.R. et al. (2004) Cell 119:1013.
7. Chih, B. et al. (2006) Neuron 51:171.
8. Sumita, K. et al. (2007) J. Neurochem. 100:154.
9. Irie, M. et al. (1997) Science 277:1511.
10. Budreck, E.C. and P. Scheiffele (2008) Eur. J. Neurosci. 26:1738.
11. Chih, B. et al. (2005) Science 307:1324.
12. Chubykin, A.A. et al. (2007) Neuron 54:919.
13. Hines, R.M. et al. (2008) J. Neurosci. 28:6055.
14. Kang, Y. et al. (2008) J. Biol. Chem. 283:2323.
15. Graf, E.R. et al. (2006) J. Neurosci. 26:4256.

Publications for Neuroligin 2/NLGN2 (5645-NL)(3)

Publications using 5645-NL

• H Shiwaku, S Katayama, M Gao, K Kondo, Y Nakano, Y Motokawa, S Toyoda, F Yoshida, H Hori, T Kubota, K Ishikawa, H Kunugi, Y Ikegaya, H Okazawa, H Takahashi Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1alpha in schizophrenia Brain, Behavior, and Immunity, 2023-03-31;111(0):32-45. 2023-03-31 [PMID: 37004758] (Bioassay, Human)
• E Camporesi, T Lashley, J Gobom, J Lantero-Ro, O Hansson, H Zetterberg, K Blennow, B Becker Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers Acta neuropathologica communications, 2021-02-01;9(1):19. 2021-02-01 [PMID: 33522967] (Reference Standard, Human)
• J Brito-More, MV Lourenco, MM Oliveira, JF Vital, FC Ribeiro, JH Ledo, LP Diniz, MH Magdesian, HM Melo, F Barros-Ara, JM de Souza, SV Alves-Leon, FC Gomes, JR Clarke, CP Figueiredo, FG De Felice, ST Ferreira Interaction of A? Oligomers with Neurexin 2? and Neuroligin 1 Mediates Synapse Damage and Memory Loss in Mice J. Biol. Chem, 2017-03-10;0(0):. 2017-03-10 [PMID: 28283575] (Bioassay, Mouse)

Bioinformatics

• Gene Symbol: NLGN2
• Uniprot:
  • EAW90197()